These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1737795)

  • 1. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis.
    Beacham DA; Wise RJ; Turci SM; Handin RI
    J Biol Chem; 1992 Feb; 267(5):3409-15. PubMed ID: 1737795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of a recombinant glycoprotein Ib alpha polypeptide which inhibits von Willebrand factor binding to the platelet glycoprotein Ib-IX complex and to collagen.
    Cruz MA; Petersen E; Turci SM; Handin RI
    J Biol Chem; 1992 Jan; 267(2):1303-9. PubMed ID: 1730650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
    Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
    J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor.
    Lankhof H; Wu YP; Vink T; Schiphorst ME; Zerwes HG; de Groot PG; Sixma JJ
    Blood; 1995 Aug; 86(3):1035-42. PubMed ID: 7620157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T; Sadler JE
    J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
    Randi AM; Jorieux S; Tuley EA; Mazurier C; Sadler JE
    J Biol Chem; 1992 Oct; 267(29):21187-92. PubMed ID: 1400429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of von Willebrand factor binding to platelets by two recognition site peptides: the pentadecapeptide of the carboxy terminus of the fibrinogen gamma chain and the tetrapeptide arg-gly-asp-ser.
    Williams S; Gralnick H
    Thromb Res; 1987 May; 46(3):457-71. PubMed ID: 3037722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein Ib can mediate endothelial cell attachment to a von Willebrand factor substratum.
    Beacham DA; Cruz MA; Handin RI
    Thromb Haemost; 1995 Feb; 73(2):309-17. PubMed ID: 7792748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.
    Cooney KA; Lyons SE; Ginsburg D
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):2869-72. PubMed ID: 1557393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
    Kroner PA; Kluessendorf ML; Scott JP; Montgomery RR
    Blood; 1992 Apr; 79(8):2048-55. PubMed ID: 1373334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.
    Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H
    Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis.
    Jumilly AL; Veyradier A; Ribba AS; Meyer D; Girma JP
    Hematol J; 2001; 2(3):180-7. PubMed ID: 11920243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.
    De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
    Cooney KA; Ginsburg D
    Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.
    Tornai I; Arnout J; Deckmyn H; Peerlinck K; Vermylen J
    J Clin Invest; 1993 Jan; 91(1):273-82. PubMed ID: 8423224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.
    Ware J; Dent JA; Azuma H; Sugimoto M; Kyrle PA; Yoshioka A; Ruggeri ZM
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2946-50. PubMed ID: 2011604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor without the A2 domain is resistant to proteolysis.
    Lankhof H; Damas C; Schiphorst ME; Ijsseldijk MJ; Bracke M; Furlan M; Tsai HM; de Groot PG; Sixma JJ; Vink T
    Thromb Haemost; 1997 May; 77(5):1008-13. PubMed ID: 9184419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine treatment of endothelial cells increases glycoprotein Ib alpha-dependent adhesion to von Willebrand factor.
    Beacham DA; Tran LP; Shapiro SS
    Blood; 1997 Jun; 89(11):4071-7. PubMed ID: 9166847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.